Macrophage Activation Syndrome: Different mechanisms leading to a one clinical syndrome

Pediatric Rheumatology

Volumn 15, Issue 1, 2017, Pages

  Bracaglia, Claudia ^a   Prencipe, Giusi ^a   De Benedetti, Fabrizio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Haemophagocytic lymphohistiocytosis; IFN ; IL 18; IL 6; Inflammasome; Macrophage activation syndrome; Natural killer

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; GLUCOCORTICOID; ANTIRHEUMATIC AGENT; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6;

ADOLESCENT; ANEMIA; ARTHRALGIA; BONE MARROW BIOPSY; CASE REPORT; CHILD; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEVER; GENE EXPRESSION PROFILING; HEPATOSPLENOMEGALY; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; HYPERFERRITINEMIA; HYPOTENSION; LEUKOPENIA; LIVER FAILURE; MACROPHAGE ACTIVATION SYNDROME; MALAISE; MALE; MISSENSE MUTATION; MYALGIA; NEUTROPENIA; PATHOGENESIS; PURPURA; REVIEW; SCHOOL CHILD; SPLENOMEGALY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TONIC CLONIC SEIZURE; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; JUVENILE RHEUMATOID ARTHRITIS; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MUTATION; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION;

EID: 85011349338     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/s12969-016-0130-4     Document Type: Review

References (48)

1. Minoia F, Davi S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160-9.
2. Hashemi-Sadraei N, Vejpongsa P, Baljevic M, Chen L, Idowu M. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting. Case Rep Hematol. 2015;2015:491567. Pubmed Central PMCID: 4338404.
3. Kilani B, Ammari L, Kanoun F, Ben Chaabane T, Abdellatif S, Chaker E. Hemophagocytic syndrome associated with visceral leishmaniasis. Int J Infect Dis. 2006;10(1):85-6.
4. Ozdemir H, Ciftci E, Ince EU, Ertem M, Ince E, Dogru U. Hemophagocytic lymphohistiocytosis associated with 2009 pandemic influenza A (H1N1) virus infection. J Pediatr Hematol Oncol. 2011;33(2):135-7.
5. Singh G, Shabani-Rad MT, Vanderkooi OG, Vayalumkal JV, Kuhn SM, Guilcher GM, et al. Leishmania in HLH: a rare finding with significant treatment implications. J Pediatr Hematol Oncol. 2013;35(3):e127-9.
6. Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170(4):539-49.
7. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984-90 e1.
8. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163(5):1253-9.
9. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-9.
10. Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol. 2016;196(6):2492-503. Pubmed Central PMCID: PMC4779709.
11. Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66(12):3486-95. Pubmed Central PMCID: 4321811.
12. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160(2):277-81.
13. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(3):441-9.
14. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58(9):2892-6. Pubmed Central PMCID: 2779064.
15. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(2):567-70.
16. Sepulveda FE, Garrigue A, Maschalidi S, Garfa-Traore M, Menasche G, Fischer A, et al. Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice. Blood. 2016;127(17):2113-21.
17. Bracaglia C, Sieni E, Da Ros M, De Fusco C, Micalizzi C, Cetica V, Ciambotti B, Coniglio ML, Insalaco A, De Benedetti F, Aricò M. Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2014;12 Suppl 1:53. Pubmed Central PMCID: PMC4184267. Epub Published online 2014 Sep 17.
18. Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood. 2015;125(10):1566-77. Pubmed Central PMCID: 4351505.
19. Jenkins MR, Rudd-Schmidt JA, Lopez JA, Ramsbottom KM, Mannering SI, Andrews DM, et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307-17. Pubmed Central PMCID: 4354371.
20. Shrestha B, Omran A, Rong P, Wang W. Report of a fatal pediatric case of hemophagocytic lymphohistiocytosis associated with pandemic influenza a (H1N1) infection in 2009. Pediatr Neonatol. 2015;56(3):189-92.
21. Dunmire SK, Odumade OA, Porter JL, Reyes-Genere J, Schmeling DO, Bilgic H, et al. Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. PLoS One. 2014;9(1):e85422. Pubmed Central PMCID: 3894977.
22. Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. 2016;213(7):1180-8.
23. Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, et al. Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64(5):1680-8.
24. Caiello I, Minnone G, Holzinger D, Vogl T, Prencipe G, Manzo A, et al. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS One. 2014;9(10):e107886. Pubmed Central PMCID: PMC4182736.
25. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142(3):292-6.
26. Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Strippoli R, De Benedetti F. Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Pediatr Rheumatol. 2014;12 Suppl 1:56.
27. Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712-22.
28. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289-98.
29. Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:55. Pubmed Central PMCID: PMC4669611.
30. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol. 2009;15(4):161-4.
31. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-55.
32. Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68(1):218-28.
33. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma. Rheumatology. 2015;54(8):1507-17.
34. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25(6):439-48.
35. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-43.
36. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood. 2011;117(24):6582-8. Pubmed Central PMCID: PMC3123024.
37. Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol. 2011;38(4):769-74.
38. Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140-6. Pubmed Central PMCID: 4177369.
39. Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135-9. Pubmed Central PMCID: PMC4177367.
40. Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. 2013;40(6):761-7.
41. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-γ and interferon-γ induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166-72.
42. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207-15. Pubmed Central PMCID: 3863330.
43. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264-77. Pubmed Central PMCID: 3104738.
44. Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, et al. Use of a mouse model to identify a blood biomarker for IFNgamma activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl Res. 2016;S1931-5244(16):30157-8.
45. Jordan ML F, Allen C, De Benedetti F, Grom AA, Ballabio M, Ferlin WG, De Min C. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. In: American society of hematology - 57th annual meeting & exposition - LBA-3. 2015.
46. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6(1):137-54.
47. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233-46.
48. Xu XJ, Tang YM. Advances in studies on hemophagocytic lymphohistiocytosis: diagnosis and treatment. Zhonghua er ke za zhi Chinese J Pediatr. 2011;49(9):712-6.